Potential Anticancer Effect of Carvacrol Codrugs on Human Glioblastoma Cells
Loading...

Date
2021
Authors
Yazici, Aysenur
Marinelli, Lisa
Cacciatore, Ivana
Emsen, Bugrahan
Eusepi, Piera
Di Biase, Giuseppe
Turkez, Hasan
Journal Title
Journal ISSN
Volume Title
Publisher
Bentham Science Publishing Ltd
Open Access Color
OpenAIRE Downloads
OpenAIRE Views
Abstract
Background: Essential oils are considered as promising sources of novel anticancer compounds. Carvacrol (CVC), the major constituent of many aromatic plants including oregano and thymus, is endowed with curative properties on different cancers, including liver, colon, and lung. Little information is available regarding the potential of CVC for the treatment of brain cancers, notably Glioblastoma Multiforme (GBM). Objective: In this work, we investigated the in vitro effect of CVC codrugs (CVC1-8), synthesized by direct-coupled co-drug strategies, on human glioblastoma cell line (U87-MG) for the first time. Methods: Cell viability was detected by MTT and LDH assays while expression levels of important genes ( such as EGFR, NFKB1A, AKT1, AKT2, and others) associated with GBM and inflammatory pathways were detected by PCR array. Results: Results showed that CVC1-8 codrugs induced cytotoxicity and positive alterations in molecular responses on U87MG cells. Particularly, important pathways (such as PI3K/PTEN/AKT) involved in the onset and progression of GBM resulted in modulation by CVC3 and CVC8. Conclusion: Our results suggest that CVC3 and CVC8 could be suitable candidates for further investigation to develop new strategies for the prevention and/or treatment of GBM.
Description
Mardinoglu, Adil/0000-0002-4254-6090; Yazıcı, Ayşenur/0000-0002-3369-6791; Cacciatore, Ivana/0000-0001-6253-0443; Een, Bugrahan/0000-0002-9636-2596; Marinelli, Lisa/0000-0001-8611-6538; Di Stefano, Antonio/0000-0002-3042-2234;
Keywords
Anti-Proliferative Action, Codrug Strategy, Carvacrol Codrug, Glioblastoma Multiforme, Gene Expression
Fields of Science
Citation
WoS Q
Q2
Scopus Q
Q2
Source
Current Drug Delivery
Volume
18
Issue
3
Start Page
350
End Page
356
